Merck to cut jobs and costs as demand for Gardasil in China remains weak

Merck announced a $3 billion annual cost-cutting plan, including job reductions, following weaker Q2 results primarily due to a 55% decline in Gardasil sales, particularly in China. Despite missing overall revenue estimates, the company's Q2 EPS beat analyst forecasts, and its blockbuster Keytruda sales remained robust. CEO Rob Davis indicated the cuts aim to redirect investment towards new growth drivers, as Merck narrowed its full-year revenue guidance, addressing ongoing investor concerns regarding post-Keytruda revenue streams.

Analysis

Merck & Co. is initiating a significant operational restructuring designed to generate $3 billion in annual savings by 2027, a direct response to deteriorating second-quarter financial results and persistent headwinds. The primary driver for the weak performance was a 55% year-over-year collapse in Gardasil vaccine sales to $1.1 billion, substantially missing analyst estimates of $1.3 billion due to a shipment pause in China and lower demand in Japan. This sharp decline overshadowed the continued strength of its blockbuster cancer drug, Keytruda, which saw sales rise 9% to nearly $8 billion, exceeding forecasts. While the company's overall quarterly revenue of $15.8 billion fell short of consensus, its earnings per share of $2.13 surpassed expectations, aided by lower R&D costs. Management is framing the cost-cutting measures, which include job reductions and optimizing its real estate and manufacturing footprint, as a strategic reallocation of capital toward new growth drivers. This pivot is critical as the company confronts investor concerns over the eventual loss of patent protection for Keytruda toward the end of the decade. The firm's narrowed full-year revenue guidance and its 2025 EPS forecast, which aligns with market consensus, suggest an attempt to project stability amidst these strategic shifts.

Key Decisions for Investors

• Investors should closely monitor the execution of the $3 billion cost-saving plan for tangible evidence of capital being redeployed into its pipeline and recent acquisitions like Verona Pharma, as this is key to de-risking the company's long-term profile post-Keytruda.
• The 55% decline in Gardasil sales is a material headwind, and any recovery in Merck's growth trajectory will heavily depend on the resolution of the shipment pause in China and stabilization of demand in other key Asian markets.
• Despite the negative headlines, Keytruda's sustained 9% growth provides significant near-term cash flow, but investors must weigh this current strength against the company's ability to successfully navigate its operational challenges and build a diversified revenue stream for the future.
• Given the stock's negative reaction, investors should consider if the current valuation adequately prices in the Gardasil weakness or if the market is underestimating the potential long-term benefits of the aggressive restructuring and strategic pivot.